8-K filing — Protara Therapeutics, Inc. (TARA)
Filed: 2026-08-11 AccNo: 0001213900-26-087506 Size: 288 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Protara Therapeutics Q2 EPS $(0.36) Misses $(0.33) Estimate
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.33) by 9.09 percent. This is a 2.86 percent decrease over losses of $(0.35) per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 11, 2026, 12:07 PM
- Checked
- Aug 11, 2026, 12:07 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Protara Therapeutics Enters $100M At-the-Market Equity Sales Agreement With TD Cowen
$100,000,000Common StockWe have entered into a sales agreement with TD Securities (USA) LLC, or TD Cowen, dated May 13, 2026, or the Sales Agreement, relating to the sale of shares of our common stock, par value $0.001
Read original at benzinga